|The following article features coverage from the Society of Gynecologic Oncology’s 50th Annual Meeting on Women’s Cancer. Click here to read more of Cancer Therapy Advisor‘s conference coverage.|
Results from a retrospective study of patients with recurrent ovarian cancer treated with carboplatin chemotherapy showed that overall survival (OS) was significantly longer for patients treated with a carboplatin desensitization protocol (due to carboplatin hypersensitivity) compared with those who did not exhibit carboplatin hypersensitivity reactions. The findings of this study were presented at the Society of Gynecologic Oncology (SGO)’s 50th Annual Meeting on Women’s Cancer.
Hypersensitivity reactions to carboplatin can range from mild to severe, and include localized erythema, as well bronchospasm, tachycardia, and changes in blood pressure. Carboplatin desensitization protocols are administered to patients exhibiting signs and symptoms of carboplatin hypersensitivity to facilitate the administration of the recommended dose of carboplatin.
In this retrospective study of 91 patients with recurrent ovarian cancer who received more than 6 infusions of carboplatin between 2005 and 2016, OS was longer by 48 months for those who underwent carboplatin desensitization (131 months vs 83 months; P =.0094), independent of age, body mass index, disease stage, degree of surgical cytoreduction, total chemotherapy regimens, or number of carboplatin cycles received.
Interestingly, in the subgroup of patients without deleterious germline BRCA1/2 mutations, OS was 43 months longer for those who underwent carboplatin desensitization compared with those without hypersensitivity to carboplatin (114 months vs 71 months; P =.035). However, no effect of carboplatin desensitization on OS was observed in the subgroup of patients with a deleterious germline BRCA1/2 mutation who did or did not receive carboplatin desensitization (176 months vs 183 months; P =.9101).
Stage III/IV disease was identified as an independent risk factor the development of carboplatin hypersensitivity compared with earlier stages of disease (hazard ratio, 4.783; 95% CI, 1.008-22.689), although carboplatin hypersensitivity was independent of age, body mass index, number of carboplatin cycles, and degree of cytoreduction.
Read more of Cancer Therapy Advisor‘s coverage of SGO’s annual meeting by visiting the conference page.
- Altwerger G, Han C, Zeybek B, et al. Impact of carboplatin hypersensitivity and desensitization on overall survival in patients with recurrent ovarian cancer. Presented at: The Society of Gynecologic Oncology (SGO)’s 50th Annual Meeting on Women’s Cancer; Honolulu, Hawaii; March 16-19, 2019. Abstract 53.